CA
NZ
UK
AU
IND
US
NeuroOne Medical Technologies (NASDAQ:NMTC) markets the only FDA-cleared electrode platform that both records brain activity and delivers radiofrequency ablation through the same implanted device. Its OneRF system is expanding from epilepsy into facial pain, while a Zimmer Biomet distribution partnership drives sales. But a …
A former banker at JPMorgan Chase has intensified legal action against the firm, expanding a lawsuit that details allegations of sexual harassment and racial discrimination. This development underscores a growing concern regarding workplace culture in the financial industry, particularly as firms face mounting scrutiny …
NeuroSense Therapeutics (NASDAQ:NRSN) is pushing its lead ALS candidate, PrimeC, toward a Canadian New Drug Submission after a Phase 2b study showed slower functional decline and a survival signal. The clinical story has strengthened through 2026, but it remains a small, thinly capitalized biotech …
NEXGEL, Inc. (NASDAQ:NXGL), a Pennsylvania hydrogel maker, published clinical data on May 19, 2026 showing its laser-treatment patch cut plume concentration by 95.6% during laser hair removal. The finding lands weeks after the company closed a transformative acquisition that formed BIONX Surgical, even as …
John Rockliff’s purchase of a 4.42% equity position in Ebiquity marks a noteworthy development for a firm that provides consultancy and benchmark services to advertisers. While the size of the holding does not constitute a controlling interest, it does grant the investor a degree …
Niagen Bioscience, (NASDAQ:NAGE) the healthy-aging company once known as ChromaDex, built a profitable supplement business around its patented NAD+ ingredient, Niagen. Now, through a new pharmaceutical subsidiary, it is chasing something harder: an approved drug for a rare pediatric disease that currently has no …
Moody's recent upgrade of McGraw-Hill Education's debt rating is poised to reshape investor sentiment toward both the company and the broader education sector. This enhancement signals a bolstered capacity for debt repayment, setting a more favorable market tone. Investors often regard debt ratings as …
The earnings uplift coincided with the continuation of its quarterly dividend of $0.20 per share. Net interest margin rose to 3.75%, underscoring the bank’s ability to generate higher returns on its earning assets. These results position the institution favorably relative to peers as it …
The improvement was driven by stronger loan growth, higher net interest margins, and disciplined cost management. The board maintained the quarterly cash dividend at $0.14 per share. Shares closed at $13.73, reflecting a 25% rise year‑to‑date, underscoring continued investor interest.
S$NEER Policy Tightened to Counter Inflation
Please wait processing your request...